Morphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intr...
FDA Drug Recall #D-0788-2026 - Class I, August 4, 2026
Recall Summary
| Recall Number | D-0788-2026 |
| Classification | Class I - Serious risk |
| Date Initiated | August 4, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Fresenius Kabi USA, LLC |
| Location | Lake Zurich, IL |
| Product Type | Drugs |
| Quantity | 625500 syringes |
Product Description
Morphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular or Intravenous use, Rx only, Fresenius Kabi, Lake Zurich, IL. Unit of Use NDC Number 76045-004-01; Unit of Sale NDC Number 76045-004-11
Reason for Recall
Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.
Distribution Pattern
Nationwide within the USA.
Lot / Code Information
Lot #: 6402820, Exp. Date 12/2028
Other Recalls from Fresenius Kabi USA, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0827-2026 | Class I | Tyenne (tocilizumab-aazg) Injection, 400 mg/20 ... | Aug 10, 2026 |
| D-0726-2026 | Class II | Lidocaine HCl Injection, USP, 2%, 100 mg per 5 ... | Jul 16, 2026 |
| D-0725-2026 | Class II | Glycopyrrolate Injection, USP, 1 mg per 5 mL (0... | Jul 16, 2026 |
| D-0729-2026 | Class II | Xylocaine (lidocaine HCl Injection, USP), 1%, 5... | Jul 16, 2026 |
| D-0728-2026 | Class II | Xylocaine (lidocaine HCl Injection, USP), 1%, 2... | Jul 16, 2026 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.